

2022

Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids.

Ishii N, Hatakeyama S, Yoneyama T, Tanaka R, Narita T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2022 Aug 1;40(10):451.e1-8. doi: 10.1016/j.urolonc.2022.07.015.

Selective reaction monitoring approach using structure-defined synthetic glycopeptides for validating glycopeptide biomarkers pre-determined by bottom-up glycoproteomics.

Shiratori K, Yokoi Y, Wakui H, Hirane N, Otaki M, Hinou H, Yoneyama T, Hatakeyama S, Kimura S, Ohyama C, Nishimura SI.

RSC Adv (IF: 3.12; Q1). 2022 Aug 3;12(33):21385-21393. doi: 10.1039/d2ra02903k. eCollection 2022 Jul 21.

Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer.

Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Sci Rep (IF: 4.38; Q1). 2022 Aug 12;12(1):13786. doi: 10.1038/s41598-022-17973-8.

PMID: 3596212

Relationship between the cross-sectional area of the lumbar dural sac and lower urinary tract symptoms: A population-based cross-sectional study.

Oyama T, Wada K, Koyama K, Kumagai G, Tanaka S, Asari T, Imai A, Okamoto T, Hatakeyama S, Jung S, Sugimura Y, Ohyama C, Ishibashi Y.

PLoS One (IF: 3.24; Q2). 2022 Aug 11;17(8):e0271479. doi: 10.1371/journal.pone.0271479. eCollection 2022.

Relationships of low-grade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis.

Fujita N, Hatakeyama S, Momota M, Hamaya T, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Andrology (IF: 3.84; Q1). 2022 Aug 5. doi: 10.1111/andr.13259.

Association of oxidative stress with erectile dysfunction in community-dwelling men and men on dialysis.

Fujita N, Momota M, Ishida M, Iwane T, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoshikawa K, Yamaya K, Ohyama C.

Aging Male (IF: 5.89; Q1). 2022 Dec;25(1):193-201. doi: 10.1080/13685538.2022.2103113.

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.

Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Ohyama C, Habuchi T.

Genes (Basel) (IF: 3.76; Q1). 2022 Jul 5;13(7):1204. doi: 10.3390/genes13071204.

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.

Takahashi S, Narita S, Fujiyama N, Hatakeyama S, Kobayashi T, Kato R, Naito S, Sakatani T, Kashima S, Koizumi A, Yamamoto R, Nara T, Kanda S, Numakura K, Saito M, Obara W, Tsuchiya N, Ohyama C, Ogawa O, Habuchi T.

Cancer Sci (IF: 6.72; Q1). 2022 Jul 18. doi: 10.1111/cas.15488.

Kidney Transplantation in a Patient With Noonan Syndrome: A Case Report.

Kodama H, Hatakeyama S, Hamaya T, Murakami R, Murasawa H, Yamamoto H, Yoneyama T, Ohyama C. Transplant Proc (IF: 1.07; Q4). 2022 Jul 6:S0041-1345(22)00391-8. doi: 10.1016/j.transproceed.2022.03.051.

Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study.

Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

World J Mens Health (IF: 5.4; Q1). 2022 May 25. doi: 10.5534/wjmh.210230.

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.

Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Enei Y, Atsuta M, Mori K, Obayashi K, Yoshihara K, Kondo Y, Oguchi T, Sadakane I, Habuchi T, Ohyama C, Shariat SF, Egawa S.

Prostate (IF: 4.1; Q2). 2022 Oct;82(14):1322-1330. doi: 10.1002/pros.24406. Epub 2022 Jun 29.

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.

Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T.

Int J Clin Oncol (IF: 3.4; Q3). 2022 Sep;27(9):1477-1486. doi: 10.1007/s10147-022-02203-y.

Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.

Miura Y, Hatakeyama S, Narita S, Kimura T, Hata K, Yanagisawa T, Tanaka T, Ishi N, Kawamura S, Hoshi S, Ishidoya S, Mitsuzuka K, Ito A, Tsuchiya N, Egawa S, Habuchi T, Ohyama C.

Prostate (IF: 4.1; Q2). 2022 Sep;82(13):1304-1312. doi: 10.1002/pros.24404. Epub 2022 Jun 23.

Robot-assisted partial nephrectomy with minimum follow-up of 5 years: A multi-center prospective study in Japan.

Furukawa J, Hinata N, Teisima J, Takenaka A, Shiroki R, Kobayashi Y, Kanayama HO, Hattori K, Horie S, Tozawa K, Kato M, Ohyama C, Habuchi T, Kawamorita N, Eto M, Fujisawa M.

Int J Urol (IF: 3.37; Q2). 2022 Sep;29(9):1038-1045. doi: 10.1111/iju.14960. Epub 2022 Jun 15.

Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear-cell renal cell carcinoma treated with radical or partial nephrectomy.

Tanaka R, Hatakeyama S, Miura H, Hamaya T, Yoneyama T, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Jun 13. doi: 10.1111/iju.14952.

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.

Iwamura H, Hatakeyama S, Narita T, Ozaki Y, Konishi S, Horiguchi H, Kodama H, Kojima Y, Fujita N, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Sci Rep (IF: 4.38; Q1). 2022 Jun 11;12(1):9675. doi: 10.1038/s41598-022-13651-x.

Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium.

Lee AY, Allen JC Jr, Teoh JY, Kang SH, Patel MI, Muto S, Yang CK, Hatakeyama S, Zhang R, Kijvikai K, Chen H, Ohyama C, Horie S, Chan ES, Lee LS.

Int J Urol (IF: 3.37; Q2). 2022 Sep;29(9):1002-1009. doi: 10.1111/iju.14937. Epub 2022 May 25.

Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.

Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S.

World J Urol (IF: 4.23; Q1). 2022 May 21. doi: 10.1007/s00345-022-04030-2.

Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.

Fujita N, Hatakeyama S, Momota M, Narita T, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Aug;29(8):867-875. doi: 10.1111/iju.14926. Epub 2022 May 16.

TMEM2 expression is downregulated as bladder cancer invades the muscle layer.

Yoneyama MS, Yoneyama T, Tobisawa Y, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Suzuki T, Ohyama C.

Biochem Biophys Res Commun (IF: 3.58; Q3). 2022 Jul 12;613:1-6. doi: 10.1016/j.bbrc.2022.04.118.

Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.

Iwamura H, Mizuno K, Akamatsu S, Hatakeyama S, Tobisawa Y, Narita S, Narita T, Yamashita S, Kawamura S, Sakurai T, Fujita N, Kodama H, Noro D, Kakizaki I, Nakaji S, Itoh K, Tsuchiya N, Ito A, Habuchi T, Ohyama C, Yoneyama T.

Cancer Sci (IF: 6.72; Q1). 2022 Jul;113(7):2434-2445. doi: 10.1111/cas.15395. Epub 2022 May 25.

Renal metastasis of ovarian granulosa cell tumor.

Togashi K, Yoneyama T, Sutoh Yoneyama M, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Futagami M, Ohyama C.

IJU Case Rep (Report missing IFs). 2022 Mar 21;5(3):186-190. doi: 10.1002/iju5.12433.

Effect of advanced glycation end products on nocturia or sleep disorders: A longitudinal study.

Konishi S, Hatakeyama S, Imai A, Okita K, Kido K, Ozaki Y, Uemura N, Iwane T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 5;3(2):162-168. doi: 10.1002/bco2.114.

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.

Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Okuyama Y, Kojima Y, Noro D, Tokui N, Okamoto T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):146-153. doi: 10.1002/bco2.117

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.

Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):154-161. doi: 10.1002/bco2.118.

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):139-145. doi: 10.1002/bco2.119. eCollection 2022

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.

Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, Murakami R, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Saitoh H, Narumi S, Tomita H, Ohyama C.

Sci Rep (IF: 4.38; Q1). 2022 Apr 7;12(1):5876. doi: 10.1038/s41598-022-09897-0.

Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.

Togashi K, Hatakeyama S, Yoneyama T, Hamaya T, Narita T, Fujita N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Jul;29(7):733-739. doi: 10.1111/iju.14882. Epub 2022 Mar 31.

Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).

Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H.

Int J Urol (IF: 3.37; Q2). 2022 Jul;29(7):632-638. doi: 10.1111/iju.14854. Epub 2022 Mar 15.

Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.

Sasaki D, Hatakeyama S, Tanaka T, Okamoto T, Yoneyama T, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Jul;29(7):772-773. doi: 10.1111/iju.14860. Epub 2022 Mar 13.

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T.

World J Urol (IF: 4.23; Q1). 2022 May;40(5):1135-1141. doi: 10.1007/s00345-022-03963-y.

Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.

Tomida R, Miyake M, Minato R, Sawada Y, Matsumura M, Iida K, Hori S, Fukui S, Ohyama C, Miyake H, Hongo F, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Hashine K; Japanese Urological Oncology Group.

Int J Clin Oncol (IF: 3.4; Q3). 2022 May;27(5):958-968. doi: 10.1007/s10147-022-02127-7.

Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.

Tanaka T, Hatakeyama S, Noro D, Togashi K, Yoneyama T, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 May;29(5):476-478. doi: 10.1111/iju.14817.

Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥ 8 .

Morozumi K, Mitsuzuka K, Narita S, Takahashi M, Kawamura S, Tochigi T, Arai Y, Hoshi S, Shimoda J, Ishidoya S, Okamoto T, Hatakeyama S, Sakurai T, Tsuchiya N, Ohyama C, Habuchi T, Ito A.

Int J Urol (IF: 3.37; Q2). 2022 Apr;29(4):324-331. doi: 10.1111/iju.14781.

Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.

Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2022 Feb;40(2):64.e1-64.e8. doi: 10.1016/j.urolonc.2021.11.005

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.

Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W.

Int J Clin Oncol (IF: 3.4; Q3). 2022 Mar;27(3):563-573. doi: 10.1007/s10147-021-02091-8

Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.

Ozaki K, Hatakeyama S, Hamaya T, Okita K, Hashimoto Y, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Apr;29(4):362-364. doi: 10.1111/iju.14778. Epub 2021 Dec 29.

Associations of impaired grip strength and gait function with the severity of erectile dysfunction in men undergoing dialysis: a cross-sectional study.

Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Aging Male (IF: 5.89; Q1). 2022 Dec;25(1):1-7. doi: 10.1080/13685538.2021.2016690.

Management of bladder cancer in older patients.

Hatakeyama S, Narita S, Okita K, Narita T, Iwamura H, Fujita N, Inokuchi J, Matsui Y, Kitamura H, Ohyama C.

Jpn J Clin Oncol (IF: 3.02; Q3). 2022 Mar 3;52(3):203-213. doi: 10.1093/jjco/hyab187.

Simultaneous analysis of serum α 2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.

Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, Yoshimura K, Miyoshi E, Uemura H, Ohyama C, Nonomura N, Fujita K.

Br J Cancer (IF: 7.64; Q1). 2022 Mar;126(5):764-770. doi: 10.1038/s41416-021-01637-x. Epub 2021 Nov 20.

The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.

Okuyama Y, Okamoto T, Sasaki D, Ozaki K, Songee J, Hatakeyama S, Mikami T, Ohyama C.

Int Urol Nephrol (IF: 2.37; Q3). 2022 Jan;54(1):9-16. doi: 10.1007/s11255-021-03044-w. Epub 2021 Oct 29.

Butyrylcholinesterase level as an independent prognostic factor for overall survival in patients on maintenance hemodialysis: a single-center retrospective study.

Fukushi K, Okamoto T, Ozaki Y, Ozaki K, Sasaki D, Miura Y, Okuyama Y, Tanaka Y, Imanishi K, Hatakeyama S, Saitoh F, Ohyama C.

Clin Exp Nephrol (IF: 2.8; Q3). 2022 Feb;26(2):190-197. doi: 10.1007/s10157-021-02140-6. Epub 2021 Sep 28.